APA (7th ed.) Citation

I, S. G., A, V. V., RS, K., AH, K., Z, M., I, A., . . . D, A. (2025). Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 198(5), e33024. https://doi.org/10.1002/ajmg.b.33024

Chicago Style (17th ed.) Citation

I, Suzer Gamli, et al. "Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase." American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : The Official Publication of the International Society of Psychiatric Genetics 198, no. 5 (2025): e33024. https://doi.org/10.1002/ajmg.b.33024.

MLA (9th ed.) Citation

I, Suzer Gamli, et al. "Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase." American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : The Official Publication of the International Society of Psychiatric Genetics, vol. 198, no. 5, 2025, p. e33024, https://doi.org/10.1002/ajmg.b.33024.